Abstract
Chronic hepatitis, cirrhosis of the liver and their consequences remain a global medical and social problem in the world. In the clinical practice of previous years, a variety of drugs were used as means of pathogenetic therapy, many of which turned out to be ineffective and went out of use. At the same time, widely known data on the ability of liver tissue to regenerate allow a rather high assessment of the prospects and potential possibilities of pathogenetic therapy of chronic hepatitis and cirrhosis using hepatoprotectors [1.2.5].
 Drug therapy for patients with liver pathology should always be as economical as possible. In each case, it is necessary to compare the degree of necessity of prescribing the drug and the potential danger of its side effects. In the treatment of patients with liver diseases, polypharmacy is extremely undesirable, and the prescribed doses, as a rule, should not exceed the average therapeutic and course [9.10.12].
Highlights
Annotation: Chronic hepatitis, cirrhosis of the liver and their consequences remain a global medical and social problem in the world
In the clinical practice of previous years, a variety of drugs were used as means of pathogenetic therapy, many of which turned out to be ineffective and went out of use
It is necessary to compare the degree of necessity of prescribing the drug and the potential danger of its side effects
Summary
Annotation: Chronic hepatitis, cirrhosis of the liver and their consequences remain a global medical and social problem in the world. Management of patients with chronic liver diseases (CHLD) requires significant material costs - this is payment for treatment, and indirect costs associated with temporary and permanent disability of the patient. This fact necessitates the use by doctors of modern and effective methods for the diagnosis of prevention and СhLD. We previously studied the structure and frequency of drugs used for the treatment of chronic hepatitis C [5,6,7,8,9] The results of these studies required research and the study of pharmacoeconomic aspects of the treatment of this disease. The results of this analysis are presented in table 1
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
